Abstract
Cryoprecipitate is a blood product obtained by concentrating fresh frozen plasma (FFP). It is used as fibrinogen replacement therapy for patients with massive bleeding. In Japan, it is reported that cryoprecipitate is effective to treat massive hemorrhage during surgery, however, it is rarely used for trauma. In our hospital, a total of 6 trauma patients have received cryoprecipitate. The average fibrinogen level before infusion of cryoprecipitate was 99.2 mg/dl, and that of post infusion was 179 mg/dl. The average lactate level was 4.6 mmol/l before infusion and 3.5 mmol/l after infusion. One of the 6 patients died and the other 5 patients were discharged or transferred to another hospital for further rehabilitation. No adverse effects concerning cryoprecipitate infusion were seen in these patients. Cryoprecipitate infusion enables hemostasis by rapid replacement of fibrinogen for trauma patients with hypofibrinogenemia, and it may improve the survival prognosis.
